RNDO-564

N/A

Report date: 2026/03/24 20:00:35

Base Information

Drug NameRNDO-564
Drug Alias NameRNDO-564
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD28Anti-NECTIN4
TargetsT-cell-specific surface glycoprotein CD28Nectin-4
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsUterine Cervical Neoplasms +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesRondo Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesRondo Therapeutics
Inactive CompaniesN/A
Active IndicationsSolid tumoursUrinary Bladder NeoplasmsUterine Cervical Neoplasms +[10] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A